Portfolio
A portfolio with outstanding potential
Over the last 5 years, Eclosion has invested in four highly innovative companies developing breakthrough therapeutics and addressing large unmet medical needs.
 | New Immunology approach to neurological diseases; first Monoclonal Antibody with the potential to become the first treatment to stop the progression of Multiple SclerosisDiscovery : BioMérieux, Inserm / Lyon Patients : Entered Clinical Phase 1 in 2011. Clinical Proof of concept phase 2 anticipated on Multiple sclerosis and CIDP in 2012 |
 | Enabling platform for the delivery of therapeutic proteins, from sub-lingual administration to intra-cellular delivery of SiRNa.Discovery : University of Geneva (CH), Milan (I) Patients : Preclinical phase |
 | Completely novel therapeutic approach to treat melanoma and other stem cancers, such as lung cancer and brain glioblastoma.Discovery: California Institute of Technologies (CALTECH) / Los Angeles (USA) Patients: Entered Clinical Proof-of-Concept phase on patient suffering from Metastatic Melanoma in 2011 |
 | Completely novel therapeutic pathway to treat oxygen radical-mediated pathologies such as most age-related degenerative diseases.Discovery: Spin-off from top Universities: Geneva (CH), Kyoto (J), San Antonio /Texas and Emory/Atlanta (USA). Patients: Entered Clinical Phase 1 study in 2011. Proof-of -concept Phase 2 planned to start in 2012 on Diabetic nephropaty and / or Fibrosis. |
> Click on the image to enlarge
Printer-friendly version
Send to friend